Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021
November 12, 2021 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
This final read-out of the 52-week open-label resmetirom 100 mg treatment study of 171 patients with presumed non-alcoholic steatohepatitis (NASH) and fibrosis, identified using non-invasive tests,...
Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results
November 04, 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides a summary of corporate accomplishments and reports its third quarter 2021 financial...
Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
October 04, 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
August 05, 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate...
Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer
August 02, 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases...
Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study
July 13, 2021 17:47 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension...
Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom
June 30, 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial,...
Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021
June 25, 2021 11:30 ET
|
Madrigal Pharmaceuticals, Inc.
Use of non-invasive measurements demonstrated that resmetirom: was safe and well-tolerated at 100 mg per day in non-cirrhotic NASH patients treated for 52 weeks;provided rapid and sustained...
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
June 08, 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic...
Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference
May 21, 2021 09:38 ET
|
Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and...